Benzingaยท2025-08-11 17:55Core Viewpoint - Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, potentially leading to supply shortages, with Moderna stepping in to fill gaps [1][2][3] Group 1: FDA Authorization and Vaccine Availability - The FDA may not renew the emergency use authorization for Pfizer's pediatric COVID-19 vaccine for the 2025 respiratory season, which could remove the only vaccine available for children under five [2][3] - Pfizer anticipates full FDA approval for its COVID-19 vaccine for children aged 5 to 11 this fall, but options for the youngest age group would be limited without authorization [3] Group 2: Current Vaccine Landscape - Moderna's pediatric vaccine, approved in July, is only available for children with specific health conditions, while Novavax's pediatric shot is available for children 12 and older with similar conditions [4] - The CDC is in discussions with Moderna to increase vaccine supply for young children in anticipation of potential gaps [4] Group 3: Vaccination Rates and Public Health Concerns - Health experts express concern that narrowing vaccine access could further decrease already low vaccination rates, with only 5.6% of children aged six months to four years vaccinated and 15% of children aged 5 to 17 [5] - Despite low uptake, the vaccines are noted to be highly effective in preventing hospitalization and death [5] Group 4: Regulatory Changes and Controversies - The U.S. Health and Human Services Secretary announced that the COVID-19 vaccine will no longer be recommended for pregnant women and healthy children on the CDC's immunization schedule [6] - The FDA has implemented stricter clinical trial requirements for healthy adults and limited annual booster approvals to older and high-risk Americans [7] - A lawsuit has been filed against Robert F. Kennedy Jr. for changes to COVID-19 vaccine recommendations, which plaintiffs argue undermine science and public health [8]